Condition
Suggested Conditions
- Anxiety
- Depression
- Alzheimer's Disease
- Weight Loss
- Heart Disease
- Cancer
- Asthma
Location
Search Clinical Trials
Conditions
Locations
Treatment Type
Trial Phase
Trial Status
Paid Participation
Clear All
16 Belzutifan Trials Near You
Power is an online platform that helps thousands of patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.
Learn More About PowerBelzutifan + Pembrolizumab for Kidney Cancer
Columbus, Ohio
This trial is testing a new treatment in patients who have had kidney cancer surgery. The goal is to see if this treatment can prevent the cancer from coming back. One part of the treatment stops cancer cells from surviving in low oxygen, and the other part helps the immune system attack the cancer. This approach has shown improved survival rates in treating advanced kidney cancer.
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Key Eligibility Criteria
Disqualifiers:Cardiovascular Disease, Brain Metastases, Others
Must Not Be Taking:Steroids, Immunosuppressive Drugs
1800 Participants Needed
Belzutifan vs Everolimus for Renal Cell Carcinoma
Cincinnati, Ohio
The primary objective of this study is to compare belzutifan to everolimus with respect to progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as assessed by Blinded Independent Central Review (BICR) and to compare everolimus with respect to overall survival (OS). The hypothesis is that belzutifan is superior to everolimus with respect to PFS and OS.
No Placebo Group
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Key Eligibility Criteria
Disqualifiers:CNS Metastases, Cardiac Disease, Hypertension, Hepatic Impairment, Others
Must Not Be Taking:CYP3A4 Inhibitors, CYP3A4 Inducers
755 Participants Needed
Pembrolizumab Combination Therapies for Prostate Cancer
Cleveland, Ohio
This trial tests pembrolizumab combined with other drugs in patients with advanced prostate cancer that doesn't respond to usual treatments. The treatment works by boosting the immune system to better attack cancer cells. Pembrolizumab has been previously tested in combination with chemotherapy for other cancers, showing improved response rates and progression-free survival.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Sex:Male
Key Eligibility Criteria
Disqualifiers:Autoimmune Disease, Pneumonitis, HIV, Others
Must Be Taking:Androgen Deprivation Therapy
1200 Participants Needed
HC-7366 + Belzutifan for Kidney Cancer
Cleveland, Ohio
This is a Phase 1b, open-label, multicenter, safety, tolerability and efficacy study of HC-7366 in combination with belzutifan (WELIREG™). This is a multipart study that consists of a HC-7366 monotherapy cohort, a combination dose escalation, and a combination dose expansion. Approximately 80 patients will be enrolled in this study (up to 20 patients will be enrolled into the HC-7366 monotherapy cohort, up to 30 patients into the combination dose escalation, and up to 30 patients into the combination dose expansion). The primary purpose of this study is to determine the maximum tolerated dose of HC-7366 in combination with belzutifan in patients with locally advanced (inoperable) or metastatic RCC with predominantly clear cell histology, irrespective of VHL gene mutation status.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Key Eligibility Criteria
Disqualifiers:Diabetes, Hypertension, Bipolar, Others
80 Participants Needed
Drug Combinations for Kidney Cancer
Fort Wayne, Indiana
The goal of this study is to evaluate the efficacy and safety of pembrolizumab plus belzutifan plus lenvatinib or pembrolizumab/quavonlimab plus lenvatinib versus pembrolizumab plus lenvatinib as first-line treatment in participants with advanced clear cell renal cell carcinoma (ccRCC).
The primary hypotheses are (1) pembrolizumab plus belzutifan plus lenvatinib is superior to pembrolizumab plus lenvatinib with respect to progression-free survival (PFS) and overall survival (OS), in advanced ccRCC participants; and (2) pembrolizumab/quavonlimab plus lenvatinib is superior to pembrolizumab plus lenvatinib with respect to PFS and OS, in advanced ccRCC participants.
No Placebo Group
Prior Safety Data
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Key Eligibility Criteria
Disqualifiers:CNS Metastases, Cardiac Disease, Others
Must Not Be Taking:Steroids, Immunosuppressants, Others
1653 Participants Needed
Belzutifan + Lenvatinib vs. Cabozantinib for Kidney Cancer
Fort Wayne, Indiana
This study will compare the efficacy and safety of belzutifan + lenvatinib versus cabozantinib in participants with advanced renal cell carcinoma (RCC) with clear cell component after prior therapy.
The primary hypothesis is that belzutifan + lenvatinib is superior to cabozantinib in terms of progression-free survival or overall survival.
No Placebo Group
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Key Eligibility Criteria
Disqualifiers:CNS Metastases, Cardiac Disease, Hepatic Impairment, Others
Must Not Be Taking:Belzutifan, Lenvatinib, Cabozantinib, Others
708 Participants Needed
Triple Drug Combo for Solid Cancers
Detroit, Michigan
This trial is testing a new treatment combining three drugs to help patients with difficult-to-treat cancers. The treatment aims to stop cancer growth, help the immune system fight the cancer, and cut off the blood supply to tumors.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:CNS Metastases, Cardiovascular Disease, Others
Must Not Be Taking:PD-1 Inhibitors
730 Participants Needed
Belzutifan for Advanced Cancers
Ann Arbor, Michigan
This trial is testing belzutifan, a medication given alone, in patients with advanced cancers that have specific genetic changes. The drug works by blocking a protein that helps cancer cells grow. Belzutifan showed significant response rates for both Von Hippel-Lindau disease-associated kidney cancers and other types of cancers.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:12+
Key Eligibility Criteria
Disqualifiers:CNS Metastases, Cardiac Disease, HIV, Others
Must Not Be Taking:CYP3A4 Inhibitors, CYP3A4 Inducers
322 Participants Needed
Immune and Targeted Combination Therapies for Kidney Cancer
Pittsburgh, Pennsylvania
Substudy 03A is part of a larger research study that is testing experimental treatments for renal cell carcinoma (RCC). The larger study is the umbrella study (U03).
The goal of substudy 03A is to evaluate the safety and efficacy of experimental combinations of investigational agents in participants with advanced first line (1L) clear cell renal cell carcinoma (ccRCC).
This substudy will have two phases: a safety lead-in phase and an efficacy phase. The safety lead-in phase will be used to demonstrate a tolerable safety profile for the combination of investigational agents. There will be no hypothesis testing in this study.
No Placebo Group
Prior Safety Data
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Key Eligibility Criteria
Disqualifiers:Cardiovascular Disease, Lung Disease, Autoimmune, Others
Must Not Be Taking:Immunosuppressants, Live Vaccines
400 Participants Needed
Belzutifan + Cabozantinib for Kidney Cancer
Detroit, Michigan
This is an open-label Phase 2 study which will evaluate the efficacy and safety of belzutifan in combination with cabozantinib in participants with advanced ccRCC. Belzutifan and cabozantinib will be administered orally once daily.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Brain Metastases, Hypertension, Cardiovascular, Others
Must Not Be Taking:Anticoagulants, HIF2α Inhibitors
118 Participants Needed
Belzutifan for Kidney Cancer
Pittsburgh, Pennsylvania
This study is designed to investigate belzutifan as a treatment for VHL disease associated RCC.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Metastatic Disease, Prior Belzutifan, Others
Must Not Be Taking:HIF-2α Inhibitors, Anti-VEGF
50 Participants Needed
Belzutifan for Kidney Cancer
Ann Arbor, Michigan
This trial is testing belzutifan, a medication for patients with advanced kidney cancer that hasn't responded to previous treatments. The drug works by blocking a protein that cancer cells need to grow. Researchers aim to find out if it is safe and effective for these patients. Belzutifan has received FDA approval for treating von Hippel-Lindau-associated renal cell carcinoma and has shown significant efficacy in related tumors.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1
Key Eligibility Criteria
Disqualifiers:Hypoxia, Brain Metastasis, Cardiac Disease, Others
Must Not Be Taking:Anticancer Antibodies
52 Participants Needed
Belzutifan for Kidney Cancer
Louisville, Kentucky
This study will compare the efficacy and safety of two doses of belzutifan in participants with advanced renal cell carcinoma (RCC) with clear cell component after prior therapy.
The primary hypothesis is that the higher dose of belzutifan is superior to the standard dose in terms of objective response rate (ORR).
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Hypoxia, CNS Metastases, Cardiac Disease, Hepatic Impairment, Others
Must Be Taking:Anti-PD-1/L1 Therapy
154 Participants Needed
Belzutifan + Palbociclib for Kidney Cancer
Chicago, Illinois
This trial is testing belzutifan alone and with palbociclib in patients with advanced kidney cancer who haven't responded to other treatments. Belzutifan helps starve cancer cells of oxygen, and palbociclib stops them from growing. Belzutifan (Welireg™) is an oral small molecule inhibitor of hypoxia-inducible factor (HIF)-2α, first approved in the USA for treating patients with von Hippel-Lindau (VHL) disease-associated renal cell carcinoma (RCC).
No Placebo Group
Prior Safety Data
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Key Eligibility Criteria
Disqualifiers:Hypoxia, CNS Metastases, Cardiac Disease, Others
Must Not Be Taking:Belzutifan, Palbociclib
210 Participants Needed
Belzutifan + Fulvestrant for Breast Cancer
Marietta, Georgia
The purpose of this study is to assess the efficacy and safety of belzutifan (MK-6482) plus fulvestrant compared to everolimus plus endocrine therapy (ET) (investigator's choice of fulvestrant or exemestane) in adults with estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) unresectable metastatic breast cancer. There is no formal hypothesis testing in this study.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Curative Cancer, Oral Medication Issues, Others
Must Be Taking:Endocrine Therapy
120 Participants Needed
Belzutifan for Ovarian Cancer
Boston, Massachusetts
The purpose of this research study is to see if the study drug Belzutifan is effective and safe for participants with ovarian cancer.
The name of the study drug involved in this study is:
- Belzutifan (a type of Hypoxia-Inducible Factor-2 alpha (HIF-2a) inhibitor)
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Sex:Female
Key Eligibility Criteria
Disqualifiers:HIV, Hepatitis B, Hepatitis C, Others
Must Not Be Taking:CYP3A4 Inducers, Herbal Supplements
32 Participants Needed
Why Other Patients Applied
"I changed my diet in 2020 and I’ve lost 95 pounds from my highest weight (283). I am 5’3”, female, and now 188. I still have a 33 BMI. I've been doing research on alternative approaches to continue my progress, which brought me here to consider clinical trials."
WR
Obesity PatientAge: 58
"As a healthy volunteer, I like to participate in as many trials as I'm able to. It's a good way to help research and earn money."
IZ
Healthy Volunteer PatientAge: 38
"My orthopedist recommended a half replacement of my right knee. I have had both hips replaced. Currently have arthritis in knee, shoulder, and thumb. I want to avoid surgery, and I'm open-minded about trying a trial before using surgery as a last resort."
HZ
Arthritis PatientAge: 78
"I have dealt with voice and vocal fold issues related to paralysis for over 12 years. This problem has negatively impacted virtually every facet of my life. I am an otherwise healthy 48 year old married father of 3 living. My youngest daughter is 12 and has never heard my real voice. I am now having breathing issues related to the paralysis as well as trouble swallowing some liquids. In my research I have seen some recent trials focused on helping people like me."
AG
Paralysis PatientAge: 50
"I've tried several different SSRIs over the past 23 years with no luck. Some of these new treatments seem interesting... haven't tried anything like them before. I really hope that one could work."
ZS
Depression PatientAge: 51
Know someone looking for new options?
Spread the word
Learn More About Power
We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.
Bask GillCEO at Power
Frequently Asked Questions
How much do clinical trials pay?
Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.How do clinical trials work?
After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across trials 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length is 12 months.How do I participate in a study as a "healthy volunteer"?
Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.What does the "phase" of a clinical trial mean?
The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.Do I need to be insured to participate in a medical study ?
Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.What are the newest clinical trials ?
Most recently, we added Belzutifan for Ovarian Cancer, Belzutifan + Fulvestrant for Breast Cancer and HC-7366 + Belzutifan for Kidney Cancer to the Power online platform.Popular Searches
By Condition
By Location
Other People Viewed
By Subject
By Trial
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.